STROライブシグナル | Getagraph.comで利益を最大化

買う 107916 min ago

@ $4.45

発行日: 15 2月 2024 @ 03:11

リターン: -19.46%

前回のシグナル: 2月 14 - 23:30

前回のシグナル: 売る

リターン: -4.28 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:44):

Stats
本日の出来高	255 941
平均出来高	999 409
時価総額	275.76M
EPS	$0 ( 2024-04-04 )
次の収益日	( $-0.910 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.01
ATR14	$0.00400 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Srinivasan Venkatesh	Sell	21 250	Restricted Stock Unit (RSU)
2024-04-11	Srinivasan Venkatesh	Buy	21 250	Common Stock
2024-04-11	Srinivasan Venkatesh	Sell	7 582	Common Stock
2024-03-05	Newell William J	Buy	167 000	Restricted Stock Units (RSUs)
2024-03-05	Fitzpatrick Linda A	Buy	37 100	Restricted Stock Units (RSUs)

INSIDER POWER
67.78
Last 99 transactions
Buy: 2 171 384 \| Sell: 404 320

ボリューム相関

長: 0.15 (neutral)

短: 0.22 (neutral)

Signal:(57.894) Neutral

Sutro Biopharma Inc 相関

10 最も正の相関
TNGX	0.88
CARA	0.864
EYE	0.821
SLM	0.809
ACHC	0.801
LSXMK	0.801

10 最も負の相関
ALR	-0.839
INZY	-0.833
BTBD	-0.83
INOD	-0.828
GETVV	-0.826
HYPR	-0.824
FTIV	-0.812
OCUL	-0.803
SELF	-0.802

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sutro Biopharma Inc 相関 - 通貨/商品

0.69
( moderate )

0.54
( weak )

0.00
( neutral )

0.37
( neutral )

0.77
( moderate )

0.42
( neutral )

Sutro Biopharma Inc 財務諸表

Annual	2023
収益:	$153.73M
総利益:	$146.92M (95.57 %)
EPS:	$-1.780

FY	2023
収益:	$153.73M
総利益:	$146.92M (95.57 %)
EPS:	$-1.780

FY	2022
収益:	$67.77M
総利益:	$59.48M (87.77 %)
EPS:	$-2.35

FY	2021
収益:	$61.88M
総利益:	$61.88M (100.00 %)
EPS:	$-2.29

Financial Reports:

No articles found.

Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.